Two new bills introduced in the Texas Legislature could jeopardize the care received by Medicaid patients, writes Vivian Ho, the James A. Baker III Institute Chair in Health Economics. She explains why the legislation would weaken county-owned insurance plans and raise Texans’ tax bills.
Fellow Vivian Ho discusses the sources she's following that shape her thoughts on how long the pandemic will last and what policy actions seem most promising. Baker Institute Blog: https://bit.ly/3aRTDrF
The authors explain why $100 billion allocated by the CARES act to compensate health care providers for unreimbursed expenses and lost revenue from may be woefully inadequate.
Baker Institute health policy experts provide links to some of the sources they found helpful in understanding developments in the coronavirus outbreak.
There is a flood of information about the coronavirus pandemic. In this Baker Institute blog, health policy fellow Vivian Ho provides links to some of the best sources followed by career health policy researchers.
To what lengths should we go to preserve human life? Doctors from Italy and China plan to provide a Russian volunteer with a new body. But is this ethical? Should they proceed? Nonresident scholar Ana S. Iltis explores these issues in a post on the Baker Institute Blog.
High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?
Elaine Howard Ecklund, Kirstin R.W. MatthewsJune 1, 2015
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
